Daniel B Costa

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
    D B Costa
    Br J Cancer 96:399; author reply 400. 2007
  2. pmc Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7060-7. 2008
  3. ncbi request reprint A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur J Haematol 76:432-5, 453. 2006
  4. pmc Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer
    Erik Folch
    Departments of Surgery, Medicine, Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    J Thorac Oncol 8:1438-44. 2013
  5. pmc The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
    Stephanie Heon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:4406-14. 2012
  6. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
  7. pmc Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
    Wee Lee Yeo
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Thorac Oncol 5:1048-53. 2010
  8. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
  9. pmc BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    PLoS Med 4:1669-79; discussion 1680. 2007
  10. pmc Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
    Paul A VanderLaan
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Lung Cancer 84:39-44. 2014

Detail Information

Publications41

  1. pmc Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
    D B Costa
    Br J Cancer 96:399; author reply 400. 2007
  2. pmc Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7060-7. 2008
    ..Our goal was to determine the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d, because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib...
  3. ncbi request reprint A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur J Haematol 76:432-5, 453. 2006
    ..R2407X). This case provides further evidence for a link between ATRX mutations and ATMDS, and suggests a possible role for the conserved Q-box element in ATRX function...
  4. pmc Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer
    Erik Folch
    Departments of Surgery, Medicine, Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    J Thorac Oncol 8:1438-44. 2013
    ....
  5. pmc The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations
    Stephanie Heon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Cancer Res 18:4406-14. 2012
    ....
  6. pmc Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
    Alice T Shaw
    Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Lancet Oncol 12:1004-12. 2011
    ....
  7. pmc Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
    Wee Lee Yeo
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Thorac Oncol 5:1048-53. 2010
    ..In NSCLC cell lines, both TKIs have similar micromolar inhibitory concentrations. We explored whether erlotinib at 25 mg/d (trough serum concentration similar to gefitinib 250 mg/d) would be efficacious in EGFR-mutated NSCLC...
  8. pmc Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
    Eunice L Kwak
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    N Engl J Med 363:1693-703. 2010
    ..We explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clinical trial of crizotinib (PF-02341066), an orally available small-molecule inhibitor of the ALK tyrosine kinase...
  9. pmc BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    PLoS Med 4:1669-79; discussion 1680. 2007
    ..The objective of this study was to identify the mechanism of EGFR TKI-induced apoptosis and secondary resistant mutations that affect this process...
  10. pmc Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer
    Paul A VanderLaan
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Lung Cancer 84:39-44. 2014
    ..We sought to evaluate the success and failure rate of EGFR mutation, KRAS mutation, and ALK FISH in a cohort of lung cancers subjected to routine clinical tumor genotype...
  11. pmc Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
    Susumu Kobayashi
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Thorac Oncol 8:45-51. 2013
    ..e., double or complex) EGFR mutations-where an EGFR TKI sensitizing or other mutation is identified together with a mutation of unknown clinical significance-and their pattern of response/resistance to EGFR TKIs are less well described...
  12. pmc Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib
    Stephanie Heon
    Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:5873-82. 2010
    ..However, there are incomplete data about their impact on the development and control of CNS metastases...
  13. pmc Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung
    Andrew M Brunner
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women s Hospital, Boston, Massachusetts and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts
    J Thorac Oncol 8:1434-7. 2013
    ..An open-label phase II trial with dasatinib was carried out to determine the response rates in patients with SqCC who had previously failed standard chemotherapy and to correlate responses with patient genotype...
  14. pmc Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations
    Elizabeth M Gaughan
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Lung Cancer 79:193-7. 2013
    ..We aimed to better characterize the incidence of family history of lung cancer among never smokers with NSCLC...
  15. pmc Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Av, Rabb 430, Boston, MA 02215, USA
    Lung Cancer 58:95-103. 2007
    ..We sought to compile the available phase II and prospective trials of this EGFR tyrosine kinase inhibitor (TKI) to better understand the efficacy and safety of selecting patients to receive gefitinib based on their genotype...
  16. pmc Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway
    Kim Son H Nguyen
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Clin Lung Cancer 10:281-9. 2009
    ..Ongoing preclinical and clinical research in EGFR-mutated NSCLC has the potential to significantly improve the outcomes of patients with these somatic mutations...
  17. pmc Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice
    Norihiro Yamaguchi
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
    Lung Cancer 82:31-7. 2013
    ..We sought to establish the frequency and correlates with these changes in routine patient-tumor sample pairs...
  18. pmc Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
    Norihiro Yamaguchi
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Lung Cancer 83:37-43. 2014
    ..ALK mutations have previously been implicated in only a third of resistant tumors. We sought to evaluate alternative mechanisms of resistance and preclinical strategies to overcome these in a cell line driven by EML4-ALK...
  19. pmc Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer
    Hiroyuki Yasuda
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Thorac Oncol 7:1086-90. 2012
    ..Our driving hypothesis was that one of these multi-targeted tyrosine kinase inhibitors (TKIs) would have antiproliferative activity against ROS1 translocated non-small-cell lung cancer (NSCLC)...
  20. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  21. doi request reprint EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
    Hiroyuki Yasuda
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet Oncol 13:e23-31. 2012
    ..Here, we review the literature and provide an update with an emphasis on the structural, molecular, and clinical implications of EGFR exon 20 insertions...
  22. doi request reprint Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 29:3307-15. 2011
    ..This global, randomized phase II trial examined erlotinib plus tivantinib (ARQ 197; ArQule, Woburn, MA), a novel MET inhibitor...
  23. pmc Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells
    Britta Will
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Blood 115:2901-9. 2010
    ..These data suggest that Bim is a key effector molecule in JAK2 inhibition-induced apoptosis and that targeting this apoptotic pathway could be a novel therapeutic strategy for patients with activating JAK2 mutations...
  24. ncbi request reprint Molecular testing in lung cancer: the time is now
    Haiying Cheng
    Division of Hematology Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY 10032, USA
    Curr Oncol Rep 12:335-48. 2010
    ....
  25. pmc Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer
    Gregory J Britt
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Thorac Dis 3:141-3. 2011
    ..It also emphasizes the importance of considering performance status rather than biologic age when making treatment decisions...
  26. pmc Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590
    Daniel B Costa
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States
    Lung Cancer 56:97-103. 2007
    ..This is the first comprehensive study of this transcription factor in patients with NSCLC...
  27. pmc Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
    Hiroyuki Yasuda
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Sci Transl Med 5:216ra177. 2013
    ..Our studies reveal intricate differences between EGFR mutations, their biology, and their response to EGFR TKIs. ..
  28. pmc Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing
    Daniela S Bassères
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA University of Sao Paulo, Sao Paulo, SP, Brazil
    Lung Cancer 77:31-7. 2012
    ..We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC)...
  29. pmc A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
    Zhao Chen
    Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 483:613-7. 2012
    ....
  30. ncbi request reprint Management and future directions in non-small cell lung cancer with known activating mutations
    David E Gerber
    From the Department of Medicine, Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX Department of Medical Oncology, Thoracic Oncology Section, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
    Am Soc Clin Oncol Educ Book 34:e353-65. 2014
    ..The development of TKIs for other oncogene-driven NSCLCs may expand the portfolio of precision therapies for this recalcitrant cancer. ..
  31. doi request reprint Safety of cupping during bevacizumab therapy
    Samuel J Klempner
    Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Altern Complement Med 19:729-31. 2013
    ..There are no data on the safety of cupping in patients being treated with bevacizumab...
  32. ncbi request reprint Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer
    Daniel B Costa
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 23:7740-2. 2005
  33. doi request reprint Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations
    Daniel B Costa
    J Clin Oncol 26:1182-4; author reply 1184-6. 2008
  34. doi request reprint Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations
    Daniel B Costa
    J Clin Oncol 26:686. 2008
  35. ncbi request reprint Three-year survival in metastatic non-small cell lung cancer treated with gefitinib
    Daniel B Costa
    Lung Cancer 53:123-4. 2006
  36. ncbi request reprint Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib
    Daniel B Costa
    Diabetes Care 29:1711. 2006
  37. ncbi request reprint Erlotinib-associated alopecia in a lung cancer patient
    Daniel B Costa
    J Thorac Oncol 2:1136-8. 2007
  38. ncbi request reprint To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress
    Daniel B Costa
    Lung Cancer 57:251-2. 2007
  39. pmc A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred
    Daniel B Costa
    Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
    Blood 106:4367-9. 2005
    ..Following gene transfer into tissue culture cells, there was complete absence of normally spliced alpha-spectrin gene transcripts derived from a minigene containing the IVS 22 +5 mutation...
  40. ncbi request reprint C/EBP alpha mutations in lung cancer
    Daniel B Costa
    Lung Cancer 53:253-4. 2006
  41. doi request reprint Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population
    Helen N Honma
    Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas, Rua Tessália Vieira de Camargo, 126, Cidade Universitaria Zeferino Vaz, Distrito de Barao Geraldo, Campinas, Sao Paulo, Brazil
    Lung Cancer 61:152-62. 2008
    ..The aim of our study was to measure the frequency of GSTM1, GSTT1, GSTP1*B and p53 gene polymorphisms in a Brazilian population and determine the possible contribution of these genetic variations to LC risk...